11/2/2026

speaker
Conference Operator
Operator

Good day and thank you for standing by. Welcome to the Cirrus Corp Q3 2026 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker, Tim Lee, Head of Investor Relations. Please go ahead.

speaker
Tim Lee
Head of Investor Relations

Thank you and good afternoon. I'd like to thank everyone for joining us today. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at ir.cirrus.com. With me on the call are Vivek Jayaraman, Cirrus' President and Chief Executive Officer, Kevin Green, Cirrus' Chief Financial Officer, and Dr. Nina Mufti, Cirrus' Senior Vice President, Research and Development. Cirrus issued two press releases this afternoon. One announcing your financial results for the third quarter ended September 30, 2026, and describing the company's recent business highlights. The other announcing top line results from our phase three RETA study. You can access copies of both announcements on the company's website at www.cirrus.com. I'd like to remind you that some of the statements we will make on this call relate to future events and performance rather than historical facts and are forward-looking statements. These include statements regarding financial outlook and performance, our business strategy and priorities, expected growth and market opportunities, clinical and regulatory activities, product launches and expansion, and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that can cause actual performance and results different material. Please refer to the forward-looking statement slide accompanying today's webcast, today's press releases, and risk factors in our form 10Q for the quarter ended September 30th, 2026 which we will follow shortly for important factors that can cause actual results to differ materially. We undertake no duty or obligation to update our forward-looking statements. On today's call, we will also be discussing non-GAAP financial measures including non-GAAP adjusted EBITDA. These non-GAAP measures should be considered a supplement to and not a replacement for measures presented in accordance with GAAP. For a reconciliation of non-GAAP financial measures to the most comparable GAAP financial measures to the extent reasonably available, please refer to today's press release in the slide presentation available on our website. We'll begin today with Vivek providing a business update and corporate highlights, followed by Kevin to review our financial results and expectations for the rest of 2026, and lastly, closing remarks from Vivek. And now, it's my pleasure to introduce Vivek Jayaraman, Cirrus' President and Chief Executive Officer.

speaker
Vivek Jayaraman
President and Chief Executive Officer

Thank you, Tim, and good afternoon, everyone. We appreciate you joining us today. At Cirrus, our mission is clear, to expand patient access to safer blood and establish intercepts as the standard of care for transfused blood components globally. Our third quarter kit sales represent nearly 800,000 doses of transfusable blood. Each dose represents a step toward improving patient care and enable us to extend the reach of pathogen reduction technology globally. Earlier today, we announced positive top line results from our phase three reddit study. This is another important step toward extending our pathogen reduction technology towards blood cell transfusion. Reflecting on my first quarter as CEO, I am more confident than ever in our team, our technology, and the opportunities ahead. As noted, our mission is to establish Intercept as a standard of care for transfused blood components globally. Realizing this mission requires us to drive sustained growth, deliver meaningful innovation, and build a financially strong business that can self-fund ongoing product and technology advancements. From an operating perspective, we are focused on three core priorities that support our mission. Delivering sustainable, double-digit annual growth, advancing clinical and technological innovation, and strengthening our financial foundation. Our third quarter performance reflects meaningful progress across all three priorities. Furthermore, the team executed well despite having to deal with a dynamic geopolitical and macroeconomic environment that created some near-term happens. Taken together, our quarterly performance demonstrates the value of our product in geographic breadth, along with the resilience of our team and their ability to navigate near-term obstacles. We are generating strong growth across our core franchises, are successfully transitioning our ISP business model, and our international rollout of the INT200 Illuminator is exceeding expectations. With the completion of our Phase III REDIS trial, we have built the largest library of clinical evidence in support of vaccine reduction technology and red cell transfusions. Financially, we delivered our 10th consecutive quarter of positive adjusted EBITDA, improved our margins, and generated $3 million in positive cash flow. I am proud of our team's performance this quarter. We will now discuss each of these three pillars in further detail. Worldwide product revenue increased 10% year-over-year, with U.S. performance leading the way. We've missed continued momentum in our IC franchise, as well as gains in our core, plateless franchise that solidly outpaced underlying market growth. International placements of the INT200 Illuminator also contributed to growth and helped set the foundation for further hit penetration. North American sales increased 12% and accounted for just over two-thirds of third-quarter product revenue. Intercept for platelets continues to be the standard of care in both the United States and Canada. In fact, intercept platelets are now used at all leading US hospitals that are recognized in the latest US News and World Report rankings. Our collaboration with Blood Centers America, or BCA, is helping broaden adoption. As a reminder, we entered into a nationwide agreement with BCA at the beginning of this year, and BCA member blood centers account for more than half of all blood products distributed in the US. While many BCA members were already serious customers, the agreement has created opportunities to deepen those relationships while also allowing us to secure new customers across both platelets and ISV. Through the first three quarters of the year, revenue growth from BCA member blood centers outpaced overall North American growth. Turning to ISV, hospital demand continues to increase as our value proposition gains traction. Immediate access to Fibroengine and a five-day post-op shelf life offer compelling benefits to clinicians, hospital administrators, and most importantly, patients. The longer shelf life can materially reduce waste, while the availability of free-thawed ISP can support more timely treatment in critical bleeding situations. Medical education remains important to expanding adoption. At the recent Association for the Advancement of Blood and Biotherapies annual meeting, The team from Grady Memorial Hospital Atlanta shared their real world experience with the intercept blood system, including ISC. The team at Grady first adopted ISC in September 2025. Now they keep a unit of ISC thought at all times ready to issue. Peer to peer exchanges are incredibly valuable and help clinicians learn from one another and better understand how ISC can fit into their clinical practice. We are also evolving our ISC commercial model to support broader patient access and more attractive economics. We are migrating from direct hospital sales to distribution via our blood center customers. I am pleased with the progress we made in Q3 with respect to the pronounced mixed shift from finished goods to kids' sales. Kids carry lower unit prices but offer more attractive gross margins and enable us to leverage the blood center distribution network, which greatly expands our hospital and patient reach. On a dose equivalent basis, ISC sales volume increased 7% sequentially. We are seeing continued strong performance in ISC as we approach year end and are highly confident that our ISC franchise will be a meaningful growth driver for years to come. In EMEA, our commercial organization continues to deliver solid performance in an increasingly challenging environment. Geopolitical conflicts in the Middle East and Russia, along with a strengthened U.S. dollar, created some near-term headwinds. We believe these headwinds are transient and that the underlying opportunity for our international business remains attractive. Unit placements of INC 200 and EMEA have exceeded our expectations and contributed strongly to the third quarter sales. We expect that trend to continue in the fourth quarter, and I appreciate the international team's unwavering focus on customer support. Our second priority, advancing innovation, builds on our commitment to drive some clinical and technological advances that improve transfusion medicine. New products and expanded indications can bring Intercept to more patients and increase our addressable market. This afternoon, we announced positive top-line results from our Phase III Redis trial of the Intercept blood system. Completing the study is a significant milestone in advancing our progress to extend the application of our patched-in reduction technology to red cell transfusions. We are grateful to the patients, investigators, blood centers, and Sears colleagues whose commitment made this important study possible. Over the past decade, pathogen reduction has become an integral part of the blood safety toolkit for platelets, plasma, and ISCs. We believe extending pathogen reduction to red blood cell transfusions represents an important opportunity to further improve transfusion safety and expand the reach of our technology. Let us compare the safety and efficacy of intercept-treated red blood cells with conventional red blood cells in patients requiring acute and long-term transfusion support. The study assessed a primary efficacy endpoint and two primary safety endpoints. Redis met its primary efficacy endpoint, demonstrating non-inferiority in adjusted hemoglobin increment compared with conventional red blood cells. Adjusted hemoglobin increment is a commonly used measure of RBC transfusion effectiveness. In addition, when evaluating treatment emergent adverse events in the Redis top line results, including the intercept RBC-specific antibody seen in the treatment arm, there was no statistically significant difference between the treatment and control arm. The antibodies seen were consistent with prior studies and resulted in no clinical impact. The red is top-line findings added to the clinical evidence from the STARS, SPARC, and RECIPE trials. We are encouraged by the efficacy results and will complete the full clinical analysis to further characterize the study's findings over the coming months. With respect to our CE-MARC red cell filing, Ansem continues to review our application. We recently held a constructive meeting with Ansem and are preparing responses to the questions they raised. As part of our response, we will include a full Redis clinical study report. The decision to include the Redis data into our package was well received by Ansem and will provide more clinical evidence, thereby strengthening our submission. As such, we now expect CE-MARC clearance in late 2027. Pending CIGIMARC approval, we are planning for a limited market release targeting centers of excellence in Europe. Our initial focus will be a small number of leading blood centers with the goal of generating real-world experience, which will inform our broader go-to-market strategy and approach. Turning to the U.S., we received preliminary feedback and questions from the FDA on our PMA platelet submission for the INC 200 Illuminator. We believe these questions are addressable, although scope will require us to gather some additional data. will have more visibility on approval timing once we align with the agency on the scope of these incremental data requirements. Despite the delay, we remain confident in our ability to successfully navigate the regulatory process and bring these technologies to market. In parallel, we will continue to drive ongoing share capture in existing markets and further strengthen the body of real-world experience we are gaining with our technology. Our third priority is to strengthen our financial foundation. We made good progress last quarter, and this is enabling us to self-end investments in both market expansion and product innovation. As we grow, we expect to generate greater leverage from our established commercial infrastructure and improve our overall profitability. Our third quarter results reflect this momentum, as evidenced by our improving margin profile, our 10th consecutive quarter of positive adjusted EBITDA, and the generation of meaningful cash flow from operations. We will balance that progress with disciplined investment in the technologies and capabilities that support future growth. Our goal is to build a profitable business that can increasingly fund its own development and expand access to safer blood. With that, I will turn the call over to Kevin to discuss our third quarter financial results in Greater DeHill.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API